Does Rallies show Form 4 insider transactions for ARVN?

Yes. Rallies tracks ARVN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ARVN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ARVN. It does not provide personalized investment advice.

ARVN (Arvinas, Inc) Stock Analysis - Insider Trades

Arvinas, Inc (ARVN) is a publicly traded Healthcare sector company. As of May 21, 2026, ARVN trades at $9.10 with a market cap of $566.50M and a P/E ratio of -1.34. ARVN moved +6.43% today. Year to date, ARVN is -18.53%; over the trailing twelve months it is +37.05%. Its 52-week range spans $5.90 to $29.61. Analyst consensus is buy with an average price target of $15.20. Rallies surfaces ARVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ARVN stock inside the company?

Recent ARVN insider activity includes Berkowitz Noah sold 6.43K, Morrison Briggs bought 20.00K, Houston John G sold 4.69K, Houston John G sold 18.82K, and Houston John G sold 11.79K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ARVN Key Metrics

Key financial metrics for ARVN
Metric	Value
Price	$9.10
Market Cap	$566.50M
P/E Ratio	-1.34
EPS	$-6.62
Dividend Yield	0.00%
52-Week High	$29.61
52-Week Low	$5.90
Volume	0
Avg Volume	0
Revenue (TTM)	$78.50M
Net Income	$-367.30M
Gross Margin	0.00%

Recent ARVN Insider Trades

Berkowitz Noah sold 6.43K (~$71.43K) on Mar 18, 2026.
Morrison Briggs bought 20.00K (~$268.07K) on Mar 6, 2026.
Houston John G sold 4.69K (~$62.07K) on Feb 27, 2026.
Houston John G sold 18.82K (~$249.20K) on Feb 27, 2026.
Houston John G sold 11.79K (~$154.88K) on Feb 27, 2026.

Latest ARVN News

Barclays Raises Arvinas Price Target to $20 After VEPPANU Approval — May 13, 2026
Arvinas, Pfizer Secure Exclusive Global License for Rigel’s VEPPANU PROTAC — May 12, 2026
Arvinas Gains FDA Approval for VEPPANU, Licenses Rights to Rigel — May 12, 2026
Arvinas’ ARV-102 Delivers >50% CSF LRRK2 Degradation and Biomarker Reductions — Mar 18, 2026
Arvinas to Unveil Phase 1 Safety and PK/PD Data for PROTAC ARV-102 — Mar 11, 2026

ARVN Analyst Consensus

17 analysts cover ARVN: 0 strong buy, 9 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.20.

Common questions about ARVN

Who is trading ARVN stock inside the company?: Recent ARVN insider activity includes Berkowitz Noah sold 6.43K, Morrison Briggs bought 20.00K, Houston John G sold 4.69K, Houston John G sold 18.82K, and Houston John G sold 11.79K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ARVN?: Yes. Rallies tracks ARVN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ARVN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ARVN. It does not provide personalized investment advice.